TipRanks
Advertisement
Advertisement
Viridian Therapeutics reports EPS ($1.05), consensus ($1.03)
PremiumThe FlyViridian Therapeutics reports EPS ($1.05), consensus ($1.03)
2M ago
Viridian Therapeutics sees cash runway through profitability
Premium
The Fly
Viridian Therapeutics sees cash runway through profitability
2M ago
“Stay Invested”: Wells Fargo Picks 2 Stocks to Buy as It Stays Bullish on the Market
Premium
Market News
“Stay Invested”: Wells Fargo Picks 2 Stocks to Buy as It Stays Bullish on the Market
3M ago
Viridian Initiated at Buy as Lumivoa FDA Approval Transitions Company to Commercial Stage; $35 Price Target Reiterated
PremiumRatingsViridian Initiated at Buy as Lumivoa FDA Approval Transitions Company to Commercial Stage; $35 Price Target Reiterated
3M ago
Wells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform
Premium
The Fly
Wells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform
3M ago
Viridian Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
Premium
The Fly
Viridian Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
3M ago
Viridian Therapeutics Fully Repays Loan, Ends Agreement
PremiumCompany AnnouncementsViridian Therapeutics Fully Repays Loan, Ends Agreement
5M ago
Viridian Therapeutics secures WuXi deal for veligrotug manufacturing
Premium
Company Announcements
Viridian Therapeutics secures WuXi deal for veligrotug manufacturing
5M ago
Viridian Therapeutics price target lowered to $26 from $27 at Evercore ISI
Premium
The Fly
Viridian Therapeutics price target lowered to $26 from $27 at Evercore ISI
5M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―